<DOC>
	<DOCNO>NCT00502203</DOCNO>
	<brief_summary>The goal clinical research study find combination paclitaxel carboplatin chemotherapy shrink slow growth mixed mullerian tumor ( MMMT ) uterus .</brief_summary>
	<brief_title>Paclitaxel Carboplatin Women With Malignant Mixed Mullerian Tumors ( MMMT ) Uterus</brief_title>
	<detailed_description>Before treatment start , patient complete check-up , blood test , chest x-ray , CT scan . Other scans test do need . Women able child must negative urine pregnancy test . A blood sample take routine test week treatment month treatment end . Patients also ask complete two questionnaire start treatment , Courses 3 5 , end treatment . These questionnaire help researcher understand drug affect patient ' daily life also identify side effect cause treatment . Each questionnaire take 10 minute complete . Patients study give paclitaxel carboplatin catheter ( tube ) place vein . Paclitaxel give first ( 3 hour ) follow carboplatin ( 1 hour ) . All treatment give outpatient department M.D . Anderson Cancer Center . Patients may receive 6 course treatment . If disease get bad intolerable side effect occur , patient take study . -Before course treatment , patient checkup . At checkup , patient physical exam blood test . Another CT scan do third course treatment . A complete physical exam CT scan also do end treatment . This investigational study . Both study drug FDA approve . Their use together study experimental . A total 50 patient take part multicenter study . About 35 enrol M. D. Anderson .</detailed_description>
	<mesh_term>Mixed Tumor , Mullerian</mesh_term>
	<mesh_term>Carcinosarcoma</mesh_term>
	<mesh_term>Mixed Tumor , Mesodermal</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Patients histologically confirm advanced ( IIIb , IIIc , IVa IVb ) recurrent ( stage ) MMMT . 2 . Prior chemotherapy permit exception patient previously treat platinum and/or taxol chemotherapy disease . 3 . Women racial ethnic group . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 . 5 . Expected survival &gt; /= 12 week . 6 . Patients must recover side effect prior therapy ( chemotherapy , surgery , radiation ) enter study . 7 . Adequate liver , renal , bone marrow function , define : total bilirubin value &lt; /= 1.5 mg/dL ; serum glutamic pyruvic transaminase ( SGPT ) &lt; /= 2 time upper limit normal &lt; /= 5 time upper limit normal liver metastasis present ; serum creatinine &lt; /= 1.5 mg/dL ; Absolute neutrophil count ( ANC ) &gt; /= 1,500/ul ; platelet count &gt; /= 100,000/ul . All qualify laboratory parameter must determine within 1 week prior first treatment . 8 . Participants must agree practice approve method birth control ( applicable ) . 9 . Patients must sign institutionally approve informed consent . 1 . Patients Zubrod performance status 3 great . 2 . Concurrent cancer chemotherapy , radiotherapy surgery . 3 . History malignancy ( except nonmelanoma skin cancer carcinoma situ cervix ) , unless complete remission therapy disease minimum 5 year . 4 . Presence know untreated brain metastasis . 5 . Overt psychosis mental disability otherwise incompetent give inform consent . 6 . Patients active systemic infection . 7 . Patients serious intercurrent medical illness . 8 . Patients history neuropsychiatric seizure disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Uterine Neoplasms</keyword>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Malignant Mixed Mullerian Tumors</keyword>
	<keyword>MMMT</keyword>
	<keyword>Immunohistochemical marker</keyword>
</DOC>